ARS Pharmaceuticals, Inc (SPRY)
Healthcare
Biotechnology
—
5.50 $
+6.4%
vs. previous close
Closing price · As of: 3. Aug 2026
Who owns ARS Pharmaceuticals, Inc (SPRY)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 48.8% of the shares are freely tradable; institutional investors hold 95.5%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
95.5%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
16.2%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
48.8%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
32.9%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
99Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RA Capital Management, LLC | 10.94 | 10,860,977 | +0.0 | 03/31/2026 |
| Orbimed Advisors, LLC | 8.35 | 8,288,510 | +0.0 | 03/31/2026 |
| Rubric Capital Management LP | 8.06 | 8,000,000 | +29.0 | 03/31/2026 |
| Deerfield Management Co | 7.56 | 7,503,812 | +0.0 | 03/31/2026 |
| Millennium Management LLC | 6.03 | 5,982,919 | +88.8 | 03/31/2026 |
| BlackRock Inc | 5.05 | 5,012,254 | -1.4 | 03/31/2026 |
| Aberdeen Group PLC | 4.14 | 4,113,617 | +15.7 | 03/31/2026 |
| SR ONE CAPITAL MANAGEMENT, LP | 4.04 | 4,012,903 | +0.0 | 03/31/2026 |
| State Street Corp | 3.67 | 3,644,966 | +13.1 | 03/31/2026 |
| Franklin Resources Inc | 3.30 | 3,278,549 | +28.9 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.